Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 10/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519358 | 0.91 | HCRTR1 (0.60) | HCRTR1HCRTR2PDPK1PDE10AALDH1A1 | |
| SCHEMBL15520392 | 0.88 | HCRTR1 (0.54) | HCRTR1HCRTR2 | |
| SCHEMBL15520078 | 0.82 | HCRTR1 (0.55) | HCRTR1HCRTR2 | |
| SCHEMBL15520281 | 0.81 | HCRTR2 (0.53) | HCRTR1HCRTR2PDE10A | |
| SCHEMBL15519543 | 0.80 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL15519484 | 0.80 | HCRTR1 (0.63) | HCRTR1HCRTR2PDE10A | |
| SCHEMBL15603598 | 0.73 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL15521997 | 0.73 | HCRTR1 (0.39) | HCRTR1HCRTR2PDPK1PDE10AMAPT | |
| SCHEMBL15520162 | 0.73 | HCRTR1 (0.67) | HCRTR1HCRTR2 | |
| SCHEMBL15520600 | 0.72 | HCRTR1 (0.60) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2708537-A1 | HETEROAROMATIC RING DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | HCRTR2, HCRTR1, HTT | HCRTR1 2/4885HCRTR2 1/4885PDPK1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.